Doctors say GLP-1 medicines can transform care for some people with obesity, but warn against cosmetic use, unapproved products and abandoning long-term lifestyle support.
GLP-1 medicines, once best known for helping people with type 2 diabetes control blood sugar, have moved into the centre of a wider debate about obesity treatment, cosmetic weight loss and the risks of using prescription drugs as quick fixes. The World Health Organization says these therapies mimic a natural hormone that helps regulate appetite and glucose, while the Mayo Clinic notes that they are generally intended for people who meet specific medical criteria and are used as part of a broader weight-management plan rather than on their own.
That tension was evident in a discussion featuring diabetologist and endocrinologist Shashank Joshi and fitness entrepreneur Jitendra Choksi. Joshi argued that, when properly prescribed, GLP-1 drugs can improve health outcomes for patients with obesity and related conditions, while Choksi warned that the growing popularity of injections risks distracting people from prevention, nutrition and exercise. The divide reflects a larger question now facing doctors and patients alike: whether these medicines should be seen as treatment for a chronic condition or as a shortcut to a slimmer appearance.
For some patients, the answer is straightforward. Health organisations including Mayo Clinic and Healthline say GLP-1 drugs can be appropriate for people with obesity, particularly when excess weight is linked with conditions such as diabetes or elevated cardiovascular risk. The drugs can reduce appetite and food intake, and many patients lose meaningful weight under medical supervision. But those benefits come with caveats. Side effects are possible, costs can be high and the effects may fade after treatment stops, making follow-up and long-term planning essential.
That long-term issue is one of the most important parts of the debate. The Mayo Clinic and Kaiser Permanente both note that weight regain after stopping treatment is a real concern for some patients, which means these medicines should not be treated as temporary event-driven tools. Joshi’s view, as described in the discussion, was that treatment should be tailored to the individual, with decisions based on overall health rather than the number on the scale alone. For patients with sleep apnoea, heart risk or kidney complications, he said the goal is broader than simple weight reduction.
The conversation also touched on a more sensitive issue: how people talk about obesity itself. Choksi compared using a weight-loss injection to taking a shortcut, but Joshi rejected that framing, arguing that obesity and diabetes are medical conditions, not moral failures. That distinction matters because stigma can discourage people from seeking help. At the same time, experts cited by the Mayo Clinic, the WHO and Healthline stress that medication is not a replacement for healthier eating, regular exercise and other behaviour changes that support lasting results.
Regulation and safety remain central concerns. The US Food and Drug Administration has warned about unapproved compounded GLP-1 products used for weight loss, saying they may not have the same review for safety, quality or effectiveness as approved medicines. That warning underscores the importance of prescriptions from licensed clinicians and proper monitoring. The broader lesson from the debate is that GLP-1 drugs may be valuable for the right patients, but they are not suitable for everyone who wants to lose weight quickly, and they work best when they are part of a medically supervised, longer-term plan.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
